实体瘤反应评估标准（RECIST）v1.1 非靶病灶评估的要点与陷阱。
Pearls and pitfalls of response evaluation criteria in solid tumors (RECIST) v1.1 non-target lesion assessment.
机构信息
Department of Diagnostic Imaging, Moffitt Cancer Center, 12902 Magnolia Dr., Tampa, FL, 33612, USA.
Department of Radiology, University of South Florida, 2 Tampa General Circle, STC 7028, Tampa, FL, 33606, USA.
出版信息
Abdom Radiol (NY). 2019 Feb;44(2):766-774. doi: 10.1007/s00261-018-1752-4.
Abstract
Oncologic imaging is an important facet of abdominal imaging that radiologists encounter nearly every day. Many oncology clinical trials utilize response evaluation criteria in solid tumors (RECIST) version 1.1 which divides tumor sites into target and non-target lesions. Although RECIST v1.1 provides clear instructions regarding the use of imaging in clinical trials, errors in response assessment still occur using these criteria. This is especially true of response assessment with regards to non-target lesions which involve rules which are less well-defined and somewhat subjective. This pictorial essay will review RECIST v1.1 guidelines and common non-target lesion errors which can occur at baseline and follow-up response assessment.
摘要
肿瘤影像学是腹部影像学的一个重要方面，放射科医生几乎每天都会遇到。许多肿瘤临床试验都使用实体瘤反应评估标准（RECIST）1.1 版，该标准将肿瘤部位分为靶病灶和非靶病灶。尽管 RECIST v1.1 为临床试验中使用影像学提供了明确的指导，但使用这些标准进行反应评估仍会出现错误。在非靶病灶的反应评估方面尤其如此，因为这些规则定义不太明确，有些主观。本文综述了 RECIST v1.1 指南和在基线和随访反应评估中可能出现的常见非靶病灶错误。
相似文献
1
Pearls and pitfalls of response evaluation criteria in solid tumors (RECIST) v1.1 non-target lesion assessment.
Abdom Radiol (NY). 2019 Feb;44(2):766-774. doi: 10.1007/s00261-018-1752-4.
2
Pitfalls in RECIST Data Extraction for Clinical Trials: Beyond the Basics.
Acad Radiol. 2015 Jun;22(6):779-86. doi: 10.1016/j.acra.2015.01.015. Epub 2015 Mar 18.
3
A Radiologist's Guide to Response Evaluation Criteria in Solid Tumors.
Curr Probl Diagn Radiol. 2019 Nov-Dec;48(6):576-585. doi: 10.1067/j.cpradiol.2018.07.016. Epub 2018 Aug 2.
4
[Comparison of RECIST 1.1 and iRECIST for Response Evaluation in Solid Tumours].
Klin Onkol. 2017 Winter;30(Supplementum3):32-39. doi: 10.14735/amko20173S32.
5
Response evaluation for immunotherapy through semi-automatic software based on RECIST 1.1, irRC, and iRECIST criteria: comparison with subjective assessment.
Acta Radiol. 2020 Jul;61(7):983-991. doi: 10.1177/0284185119887588. Epub 2019 Nov 18.
6
Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.
J Clin Oncol. 2016 May 1;34(13):1510-7. doi: 10.1200/JCO.2015.64.0391. Epub 2016 Mar 7.
7
Tumor response assessment: comparison between unstructured free text reporting in routine clinical workflow and computer-aided evaluation based on RECIST 1.1 criteria.
J Cancer Res Clin Oncol. 2017 Dec;143(12):2527-2533. doi: 10.1007/s00432-017-2488-1. Epub 2017 Aug 19.
8
Revised Modified Response Evaluation Criteria in Solid Tumors for Assessment of Response in Malignant Pleural Mesothelioma (Version 1.1).
J Thorac Oncol. 2018 Jul;13(7):1012-1021. doi: 10.1016/j.jtho.2018.04.034. Epub 2018 May 9.
9
Importance of volumetric measurement processes in oncology imaging trials for screening and evaluation of tumors as per response evaluation criteria in solid tumors.
Asian Pac J Cancer Prev. 2014;15(5):2375-8. doi: 10.7314/apjcp.2014.15.5.2375.
10
[RECIST and the radiologist].
Radiologia. 2014 May-Jun;56(3):193-205. doi: 10.1016/j.rx.2012.03.010. Epub 2012 Aug 16.
引用本文的文献
1
Regarding RECIST in retrospective studies.
Oncologist. 2025 Jul 4;30(7). doi: 10.1093/oncolo/oyaf182.
2
Octreotide infusion pump in patients with functional neuroendocrine tumors and refractory hormonal syndrome.
Endocr Oncol. 2025 May 14;5(1):e250016. doi: 10.1530/EO-25-0016. eCollection 2025 Jan.
3
Dedicated software to harmonize the follow-up of oncological patients.
Res Diagn Interv Imaging. 2024 Sep 24;12:100051. doi: 10.1016/j.redii.2024.100051. eCollection 2024 Dec.
4
Applications of CT-based radiomics for the prediction of immune checkpoint markers and immunotherapeutic outcomes in non-small cell lung cancer.
Front Immunol. 2024 Aug 22;15:1434171. doi: 10.3389/fimmu.2024.1434171. eCollection 2024.
5
Baseline hepatobiliary MRI for predicting chemotherapeutic response and prognosis in initially unresectable colorectal cancer liver metastases.
Abdom Radiol (NY). 2024 Aug;49(8):2585-2594. doi: 10.1007/s00261-024-04492-5. Epub 2024 Jul 22.
6
Can blood-based markers predict RECIST progression in non-small cell lung cancer treated with immunotherapy?
J Cancer Res Clin Oncol. 2024 Jun 26;150(6):329. doi: 10.1007/s00432-024-05814-2.
7
Reproducing RECIST lesion selection via machine learning: Insights into intra and inter-radiologist variation.
Eur J Radiol Open. 2024 Apr 17;12:100562. doi: 10.1016/j.ejro.2024.100562. eCollection 2024 Jun.
8
Can we predict discordant RECIST 1.1 evaluations in double read clinical trials?
Front Oncol. 2023 Oct 4;13:1239570. doi: 10.3389/fonc.2023.1239570. eCollection 2023.
9
Association of Circulating Tumor Cells, Megakaryocytes and a High Immune-Inflammatory Environment in Metastatic Breast Cancer.
Cancers (Basel). 2023 Jun 28;15(13):3397. doi: 10.3390/cancers15133397.
10
Breaking down the RECIST 1.1 double read variability in lung trials: What do baseline assessments tell us?
Front Oncol. 2023 Mar 16;13:988784. doi: 10.3389/fonc.2023.988784. eCollection 2023.
本文引用的文献
1
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.
2
RECIST revisited: a review of validation studies on tumour assessment.
Eur J Cancer. 2006 May;42(8):1031-9. doi: 10.1016/j.ejca.2006.01.026. Epub 2006 Apr 17.
3
The RECIST (Response Evaluation Criteria in Solid Tumors) criteria: implications for diagnostic radiologists.
Br J Radiol. 2001 Nov;74(887):983-6. doi: 10.1259/bjr.74.887.740983.
4
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16. doi: 10.1093/jnci/92.3.205.
5
Reporting results of cancer treatment.
Cancer. 1981 Jan 1;47(1):207-14. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6.
6
Influence of measurement error on assessment of response to anticancer chemotherapy: proposal for new criteria of tumor response.
J Clin Oncol. 1984 Sep;2(9):1040-6. doi: 10.1200/JCO.1984.2.9.1040.
7
Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria.
Invest New Drugs. 1992 Nov;10(4):239-53. doi: 10.1007/BF00944177.
Zotero 插件